Alice Ma, MD
Hematology & Oncology · Chapel Hill, NCNPI 1568539658
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (40.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Shire North American Group Inc at 37.7% of the total. Reporting peaked in 2019 at $30,024 and has fallen 99.8% since, to $61 in 2025.
Across 32 payments — averaging $1323.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Shire North American Group Inc$16K
- Novo Nordisk$9K
- Takeda Pharmaceuticals U.S.A., Inc.$7K
- Pfizer$5K
- Biomarin Pharmaceutical Inc.$5K
- Vertex$61
Across 24 payments — averaging $1794.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Spark Therapeutics, Inc.$23K
- Takeda Pharmaceuticals U.S.A., Inc.$12K
- Shire North American Group Inc$9K
What the payments were for
- Consulting fees$14,61635%
- Speaking & faculty fees$17,31341%
- Grants$4531%
- Travel & lodging$9,62723%
- Food & beverage$3531%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Shire North American Group Inc | 11 | $15,988 |
| Novo Nordisk | 5 | $8,988 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $6,921 |
| Pfizer | 5 | $5,356 |
| Biomarin Pharmaceutical Inc. | 5 | $5,048 |
| Vertex | 1 | $61 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OBIZUR$16,496
How this compares
$42,362 in reported general payments places this provider in the 85th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DopteletAvatrombopag Maleate | 22 | $363,825 |
| JakafiRuxolitinib Phosphate | 19 | $162,040 |
| PromactaEltrombopag Olamine | 12 | $43,173 |
| EliquisApixaban | 18 | $20,470 |
| Tranexamic Acid | 83 | $10,364 |
| Mycophenolate Mofetil | 29 | $2,376 |
| Morphine Sulfate ErMorphine Sulfate | 36 | $1,862 |
| Hydroxyurea | 19 | $838 |
| Oxycodone Hcl | 39 | $567 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $433 |
| Celecoxib | 14 | $279 |
| Prednisone | 15 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $5,356 | $20,47018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 358 hematology & oncology providers in North Carolina.
Other hematology & oncology in Chapel Hill
- Jared WeissChapel Hill$217K
- Joshua ZeidnerChapel Hill$208K
- Brandi ReevesChapel Hill$198K
- Nigel KeyChapel Hill$174K
- Norman SharplessChapel Hill$125K
- Lisa CareyChapel Hill$51K
- Thomas SheaChapel Hill$24K
- Juneko Grilley OlsonChapel Hill$24K
- Amit MehtaCary$4.3M
- Michael MorseDurham$2.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.